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OBJECTIVES We sought to investigate the possibility that lung diffusing capacity reduction observed in
chronic heart failure is reversible in the short term.
BACKGROUND Mechanical properties of the lung usually ameliorate with antifailure treatment including
drugs, ultrafiltration and heart transplantation, whereas lung diffusion rarely improves.
METHODS We studied the mechanical properties of the lung (pulmonary function tests with determi-
nation of alveolar volume, extravascular lung fluids and lung tissue), lung diffusion for carbon
monoxide (DLco), including membrane diffusing capacity (Dm), pulmonary capillary blood
volume (Vc) and pulmonary hemodynamics, in 28 patients with stable chronic heart failure,
before a single session of extracorporeal ultrafiltration (3973 6 2200 ml) and four days
thereafter. Lung mechanics and diffusion were also evaluated in 18 normal subjects.
RESULTS Vital capacity, forced expiratory volume (1 s) and maximal voluntary ventilation were lower
in patients when compared with normal subjects, and increased after ultrafiltration from
2.1 6 0.7 to 2.5 6 0.7(l)*, 1.7 6 0.5 to 2.0 6 0.6(l)* and 67 6 25 to 79 6 26 (l/min)*,
respectively (* p , 0.02 vs. pre-ultrafiltration). Post-ultrafiltration alveolar volume was
augmented, while lung tissue, body weight (;6 kg), chest X-ray extravascular lung water
score and pulmonary vascular pressure were reduced. Heart dimensions (echocardiography)
remained unchanged. DLco, Dm and Vc were 29.0 6 5.0 ml/min/mm Hg, 47.0 6 11.0
ml/min/mm Hg, 102 6 20 ml in normal subjects and 17.1 6 4.0#, 24.1 6 6.5#, 113 6 38
and 17.0 6 5.0#, 24.8 6 7.9#, 100 6 39 in patients before and after ultrafiltration,
respectively (# 5 p , 0.01 vs. controls).
CONCLUSIONS In chronic heart failure, ultrafiltration improves volumes and mechanical properties of the
lung by reducing lung fluids. Diffusion is unaffected by ultrafiltration, suggesting that, in
chronic heart failure, the alveolar-capillary membrane abnormalities are fluid-independent. (J
Am Coll Cardiol 2000;36:1600–4) © 2000 by the American College of Cardiology
In heart failure patients the mechanical properties of the
lung, as well as lung diffusing capacity, are frequently altered
(1–4), and pulmonary function tests often identify a restric-
tive pattern (2,4). Pulmonary mechanical abnormalities can
be reduced, or even resolved, with different sorts of heart
failure treatment, including drugs (5–7), ultrafiltration (8,9)
and heart transplantation (10). On the contrary, lung
diffusing capacity has been shown to improve with
angiotensin-converting enzyme inhibitors (5–7), but not
with other antifailure drugs, such as diuretics (11), AT1-
blockers (6,7), hydralazine (5) and beta-blockers (12). Fur-
thermore, heart transplantation, which is probably the most
effective antifailure treatment, does not affect and may even
worsen lung diffusing capacity. Data on lung diffusion after
ultrafiltration are lacking (13–15). Raughton and Foster
(16) showed that lung diffusion can be split into two
subcomponents: alveolar-capillary membrane resistance and
volume of pulmonary capillary blood. Indeed, 1/DLco 5
1/Dm 1 1/uVc, where DLco is lung diffusion capacity for
carbon monoxide, Dm is alveolar-capillary membrane resis-
tance, u is red blood cell resistance and Vc is pulmonary
capillary blood volume available for gas exchange. Dm
reduces as heart failure worsens (4,17), whereas Vc increases
only when heart failure is severe (17). Increased Vc is seen
as a partial compensatory mechanism to alveolar capillary
membrane reduction (17). Lack of improvement in lung
diffusing capacity after heart transplantation (13–15) sug-
gests that normalization of pulmonary capillary blood vol-
ume, following pulmonary hemodynamic improvement, is
not counterbalanced by an increase of alveolar capillary
membrane diffusing capacity. This supports the concept that
chronic heart-failure-induced membrane damage is, at least
in part, not reversible. Mettauer et al. (18) reported a
correlation between duration of heart failure and alveolar-
capillary membrane conductance defects. However, several
factors, beyond the duration of a hemodynamic event, might
influence alveolar capillary membrane diffusing capacity
after heart transplant: (a) increase of lung volume due to
heart size reduction (10), (b) chest wall and chest muscle
damage with surgery, and (c) use, in the postsurgical period,
of drugs that might alter lung diffusion. Indeed, lung
diffusion is not merely ruled by pressure gradients, but also
by fluid movement across the alveolar-capillary membrane,
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which has a relevant active component (19–21). Accord-
ingly, a correlation between lung diffusing capacity decline,
after heart transplant, and cyclosporine plasma levels was
noted by Casan et al. (22).
Therefore, we decided to study the behavior of pulmo-
nary mechanics and lung diffusing capacity in heart failure
before and after a therapeutic technique that induces pul-
monary hemodynamic improvement without heart volume
changes, and without the confounding effects of surgery or
drugs possibly interfering with lung diffusion (5,22). We
aimed at knowing how much impairment is due to alveolar
fluid retention and how much to nonhemodynamic and
possibly nonreversible membrane damage. We used extra-
corporeal ultrafiltration, which is known to reduce lung
water content, right atrial and pulmonary vascular pressure,
and to improve patients’ clinical condition, which includes
exercise capacity as well as pulmonary mechanical properties
(8,9).
METHODS
Patient population. We studied 28 patients with severe
heart failure (New York Heart Association [NYHA] class
III and IV) in stable clinical condition and therapeutic
regimen. All patients belonged to a cohort of heart failure
subjects regularly followed at the Heart Failure Unit of the
Institute of Cardiology, University of Milan. Twenty-one
patients were males and seven females (mean age 66 6 8
years). Heart failure etiology was ischemic heart disease in
15 subjects, idiopathic cardiomyopathy in 9 and valvular
heart disease in 4. Exclusion criteria were: left ventricular
ejection fraction (by echocardiography) .35%, primary
pulmonary disease, unstable angina or recent myocardial
infarction, artificial pacemakers. Drug treatment included
diuretics (28 cases), angiotensin-converting enzyme inhibi-
tors (22 cases), digoxin (19 cases), nitrates (9 cases) and
amiodarone (11 cases). Therapy remained unchanged
throughout the study. Eighteen control subjects were also
investigated (12 men and 6 women, mean age 61 6 7 years)
for pulmonary function test measurements. The study was
approved by the local Ethical Committee and all patients
provided informed written consent to the study.
Echocardiographic evaluation. Patients underwent echo-
cardiographic measurement of left ventricle volumes and
ejection fraction.
Pulmonary function tests. Pulmonary function tests in-
cluded forced expiratory volume in 1 second (FEV1), vital
capacity (VC), and maximal voluntary ventilation (MVV)
measurements. For MVV we used the greater between
measured MVV over 12 s and FEV1 3 40 (23). Alveolar
volume was obtained by methane dilution technique. We
also determined DLco using the single breath constant
expiratory flow technique. DLco measurement was cor-
rected for the subjects’ hemoglobin concentration, according
to Coats et al. (24). We also measured the DLco subcom-
ponents Dm and Vc (16). Lung tissue was calculated by
applying the Wilson formula, which considers the decay of
methane, carbon monoxide and acetylene during constant
expiratory flow (25–27).
Chest X-ray. Extravascular lung fluid content was assessed
with a radiographic score (28).
Hemodynamic evaluation. Hemodynamic evaluation was
carried out using Swan-Ganz catheterization of the pulmo-
nary artery (internal jugular vein approach). We measured
pulmonary artery pressure, pulmonary wedge pressure, right
atrial pressure and cardiac output (thermodilution, triplicate
measures) after at least 30 min of complete rest.
Ultrafiltration. A single session of ultrafiltration was per-
formed using a previously described technique (8,9). In
brief, a diafilter (D20SF Amicon) was inserted into a
veno-venous extracorporeal circuit that was connected to a
femoral vein through a percutaneous double-lumen
Y-shaped catheter for blood withdrawal and reinfusion.
Patients were treated with IV heparin. Blood was propelled
by a peristaltic pump. Ultrafiltration was interrupted when
right atrial pressure was reduced by 50% or red pack cell
volume increased by three points.
Study design. Patients were admitted to the hospital and
their clinical condition, including stability, was assessed.
Thereafter, they underwent echocardiogram, chest X-ray,
pulmonary function tests, lung tissue and DLco measure-
ments, including Dm and Vc (day 21). The next day, the
first hemodynamic study was performed and was followed
by a single-session ultrafiltration (day 0). Four days after,
clinical evaluation, hemodynamic measurements, echocar-
diogram, chest X-ray and the pulmonary function tests were
repeated. Normal subjects underwent only pulmonary func-
tion tests.
Statistical analysis. Data are reported as mean 6 1 stan-
dard deviation. Comparisons were made by paired or
unpaired t tests as, appropriate. When needed, because of
multiple comparisons, the Bonferroni correction was ap-
plied. A value of p , 0.05 was considered statistically
significant.
RESULTS
Ultrafiltration was safely carried out in all patients without
untoward effects. The ultrafiltrate amount was 3,973 6
2,200 ml and ranged from 1,050 to 11,000 ml. Mean body
weight was 77.2 6 13.5 kg before ultrafiltration and 71.4 6
12.7 kg four days after the procedure (p , 0.001). At the
fourth day after ultrafiltration patients clinical conditions
Abbreviations and Acronyms
DLco 5 lung diffusion for carbon monoxide
Dm 5 alveolar-membrane diffusing capacity
FEV1 5 forced expiratory volume in 1 s
MVV 5 maximal voluntary ventilation
NYHA 5 New York Heart Association
Vc 5 pulmonary capillary blood volume available for
gas exchange
VC 5 vital capacity
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improved and NYHA functional class reduced from 3.6 6
0.6 to 2.8 6 0.6 (p , 0.01). Before ultrafiltration, left
ventricular ejection fraction and systolic and diastolic diam-
eters were 25.4 6 4.3%, 54 6 7 mm and 65 6 8 mm,
respectively, and remained unchanged four days after the
procedure. Standard pulmonary function tests are reported
in Table 1. An improvement in lung mechanics in all
subjects was observed after ultrafiltration. In contrast,
DLco, which was significantly reduced in patients compared
to normal subjects, did not increase after ultrafiltration.
Lack of variations in DLco was the result of an unchanged
Dm with a tendency of Vc to decrease (Table 2). Patients’
alveolar volume was significantly lower than normal subjects
and increased by ;10% four days after ultrafiltration. DLco,
normalized for alveolar volume, decreased after the proce-
dure, while Dm remained unchanged. Lung tissue was
increased in patients with heart failure when compared with
normal subjects by ;50% and, four days after ultrafiltration,
reduced from 620 6 180 ml to 550 6 170 ml (p , 0.02).
Considering the short time interval, this reduction was
likely due to a decrease in lung water content. Accordingly,
chest X-ray extravascular lung water score reduced from
18.4 6 3.5 to 11.2 6 3.0 (p , 0.01). Hemodynamic
parameters before and after ultrafiltration are reported in
Table 3.
DISCUSSION
The major result of the present study is that, in patients with
chronic congestive heart failure, mechanical properties and
diffusing capacity of the lung behave differently after reduc-
tion of lung fluid content, right atrial and pulmonary venous
pressures by ultrafiltration. Amelioration of mechanical
properties of the lung after ultrafiltration is due to reduction
of lung stiffness secondary to a lowered lung fluid content
(8,29). The factors that, in chronic heart failure, determine
low lung diffusing capacity are the reduction of gas surface
exchange and the impairment of membrane diffusing capac-
ity. The former is inferable from reduction of vital capacity
and alveolar volume, the latter from a low Dm. Lack of Dm
improvement, as well that of Dm normalized for alveolar
volume after the procedure, suggests that increase in the
fluid content of the alveolar capillary membrane is not the
major cause of lung diffusing capacity reduction. On the
other hand, membrane impairment may be due to an
increase in cellularity and fibrosis. Therefore, our findings
explain why Dm changes may be irreversible and not
influenced by heart transplantation (13,14,18).
Ultrafiltration was safely conducted in all subjects and, as
demonstrated by NYHA functional class reduction, allowed
improvement of the patients’ clinical condition. The present
report, however, is not intended to document the safety of
ultrafiltration or its clinical efficacy, which have been previ-
ously reported in several papers (8,9,29–32). In this study,
we utilized data on lung function, from patients with severe
heart failure who are undergoing ultrafiltration for clinical
reasons, in order to better understand the differences in the
response of lung mechanics and diffusing capacity to heart
Table 1. Standard Pulmonary Function Tests in Controls
(n 5 18) and in Chronic Congestive Heart Failure Patients
Undergoing Ultrafiltration (n 5 28)
Controls
Congestive Heart Failure Patients
Before UF Four Days after UF
VC (L) 4.7 6 1.0 2.1 6 0.7* 2.5 6 0.7*§
FEV1 (L) 3.9 6 0.9 1.7 6 0.5* 2.0 6 0.6*§
MVV (L/min) 145 6 22 67 6 25* 79 6 26*§
* 5 p , 0.01 vs. controls, § 5 p , 0.01 vs. before ultrafiltration.
FEV1 5 forced expiratory volume (1 s); MVV 5 maximal voluntary ventilation;
UF 5 ultrafiltration; VC 5 vital capacity.
Table 2. Lung Diffusing Capacity for Carbon Monoxide (DLco), Alveolar-Capillary Membrane
Diffusing Capacity for Carbon Monoxide (Dm), Capillary Volume (Vc), Alveolar Volume (Va)
and Lung Tissue (Lt) in Controls (n 5 18) and in Chronic Congestive Heart Failure Patients
Undergoing Ultrafiltration (n 5 28)
Controls
Congestive Heart Failure Patients
Before UF
Four Days
after UF
DLco (ml/min/mm Hg) 29.0 6 5.0 17.1 6 4.0* 17.0 6 5.0*
Dm (ml/min/mm Hg) 47.0 6 11.0 24.1 6 6.5* 24.8 6 7.9*
Vc (ml) 102 6 20 113 6 38 100 6 39
Va (L) 6.3 6 1.3 4.1 6 1.6* 4.6 6 1.4*§
Lt (ml) 420 6 130 620 6 180* 550 6 170*§
DLco/Va (ml/min/mm Hg/L) 4.5 6 4.3 4.3 6 0.8 3.8 6 1.0§
Dm/Va (ml/min/mm Hg/L) 7.1 6 3.0 6.0 6 2.1* 5.9 6 2.2*
* 5 p , 0.01 vs. controls, § 5 p , 0.02 vs. before ultrafiltration.
UF 5 ultrafiltration.
Table 3. Pulmonary Hemodynamics in 28 Chronic Congestive
Heart Failure Patients Before Ultrafiltration and Four
Days Thereafter
Before UF
Four Days
after UF
Cardiac index (ml/min/m2) 2200 6 200 2300 6 200
Mean pulmonary artery pressure
(mm Hg)
29 6 6 17 6 6*
Pulmonary wedge pressure
(mm Hg)
25 6 5 15 6 4*
Right atrial pressure (mm Hg) 8 6 3 5 6 3*
* 5 p , 0.01 vs. before ultrafiltration.
UF 5 ultrafiltration.
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failure treatment. Remarkably, ultrafiltration has been
shown to reduce lung fluid content and, as a consequence, to
improve lung mechanics (29) without changing heart di-
mensions (31), with no surgical trauma on the chest and
without utilization of drugs possibly interfering with lung
diffusing properties (22). The greater reduction in body
weight four days after ultrafiltration, compared to the
ultrafiltrate volume (5.8 6 3.7 Kg vs. 3973 6 2205 ml), is
not surprising in view of the ultrafiltration capability to
restore diuresis and kidney response to diuretics (32).
Vital capacity and lung tissue are inversely related to each
other in relation to the amount of interstitial fluids. Both
showed, before and after ultrafiltration, a significant inter-
subject variability in patients compared with normal subjects
(Tables 1 and 2). This variability may depend on individual
differences in intravascular pressures, on lung fluid drainage
capacity due to the unevenly enhanced fluid removal capac-
ity of various lung fluid drainage pathways in chronic heart
failure (33,34) and on heart dimension (cardiomegaly), a
major cause of lung restrictive disease in heart failure (10).
Accordingly, it has been shown for many years that pulmo-
nary wedge pressure can be predicted by chest X-ray, in
acute but not in chronic heart failure, when the above
reported mechanisms interplay (35). However, increase of
vital capacity and reduction of lung tissue observed after
ultrafiltration are as one would expect after acute lung fluid
reduction. A reduction in lung fluid is suggested by lower
right atrial and pulmonary wedge pressures and X-ray
extravascular lung score observed four days after ultrafiltra-
tion.
In chronic heart failure, DLco is impeded mainly because
Dm is reduced (17). In the present study, both overall Dm
and Dm normalized for alveolar volume were low and, more
importantly, remained unchanged after ultrafiltration. Be-
cause ultrafiltration reduced lung fluid, an increase in Dm
would be expected if augmented lung fluid were the cause of
the reduced Dm. Actually, we cannot exclude the possibility
that fluid movement from the alveolar-capillary membrane
is a very slow process. However, this seems unlikely because,
for geometrical reasons, the gas exchange surface is highly
protected by fluid overload (36) and, in all likelihood, is the
first site to be fluid-free when lung fluids are reduced.
Furthermore, our post-ultrafiltration study was carried out
four days after the procedure, an interval that is more than
enough to readjust fluid distribution in the lungs. On the
other hand, while ultrafiltration-induced effects on pulmo-
nary hemodynamics and lung fluid were appreciable, Dm
remained unchanged. This suggests that, in chronic con-
gestive heart failure, Dm reduction is not likely due to fluid
accumulation but to other causes, such as fibrosis or an
increase in cellularity of the alveolar-capillary membrane.
This finding explains why mechanical properties and dif-
fusing capacity of the lung behave differently after heart
failure treatment, which includes drugs and heart transplan-
tation. Furthermore, the findings of the present study are in
agreement with the recently developed concept that fluid
transport across the alveolar-capillary membrane is, at least
in part, an active (pump-mediated) phenomenon (19–21)
and that some antifailure drugs may act directly on the
membrane diffusing activity (5).
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